Pharmaceuticals & Biotechnology

REGENERON PHARMACEUTICALS, INC. CEO pay

Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer. Fiscal year 2024, as reported to the SEC.

Total compensation

$6.8M

$6,823,034 for fiscal 2024: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-04-24SEC accession number 0001308179-26-000340

In context

The median chief executive among 10 Pharmaceuticals & Biotechnology companies with over $10B in revenue was paid $21.2M. The middle half ranged from $17.5M to $22.4M.

Leonard S. Schleifer's total is below that median.

See how your pay compares to REGENERON PHARMACEUTICALS, INC.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: REGENERON PHARMACEUTICALS, INC.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2024. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.